Sep 10, 2019 / 02:35PM GMT
Scott Koenig - MacroGenics, Inc. - CEO, President & Director
David has been delayed. So I'll be happy to actually comment -- I mean as you know, we have a company that is sort of at a wonderful juncture in its development right now. Just to refresh your memory, we have currently 9 molecules in Phase I to Phase III development. There is a lot of focus these days on margetuximab. As you recall, margetuximab is an Fc-engineered antibody targeted to HER2. It's one of the 2 proprietary platforms that MacroGenics has developed along with our bispecific multispecific DART program.
Just to give you a little bit of sense of where we are on margetuximab. As you recall, in February of this year, we announced a positive Phase III data in a trial called SOPHIA, where we are comparing the activity in late-stage third-line metastatic breast cancer in patients who have been experienced with HERCEPTIN, Perjeta and Kadcyla. And we did a comparison against HERCEPTIN in combination with chemotherapy. We had a successful readout on the first sequential endpoint, which was PFS, where we saw an improvement in intent
MacroGenics Inc at Morgan Stanley Healthcare Conference Transcript
Sep 10, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers